C Roux1, A Thyss, M Gari-Toussaint. 1. Service d'hématologie clinique, hôpital Archet 1, CHU de Nice, 151, route de Saint-Antoine-de-Ginestière, BP 3079, 06202 Nice cedex 2, France. Electronic address: clemence413@hotmail.com.
Abstract
OBJECTIVE: Treatment of chronic lymphocytic leukaemia (CLL) is rapidly evolving, with emerging new drugs. Alemtuzumab is a monoclonal antibody recognizing CD52 antigen approved in the treatment of relapsing-refractory CLL. A frequent side effect is the immunosuppression and patients treated with alemtuzumab risk to develop fungal infections such as aspergillosis. PATIENT AND METHODS: This case report is about a patient who developed an uncommon localization of aspergillosis: prostatic and renal, after a treatment by alemtuzumab monotherapy. During the week 8 of alemtuzumab, the patient presented fever, urinary frequency and urologic symptoms. Persistance of fever with common antibiotherapy led to realize a tomography that showed prostatic and renal abscess (70mm and 29mm). It was decided to realize a prostatic biopsy. RESULTS: Histological findings showed suppurative abscess with ischemic necrosis and fungal proliferation, with branched fungal hyphae. Direct examination was negative. Culture on Sabouraud's agar revealed a mould identified as Aspergillus fumigatus. The organism was susceptible to voriconazole (MIC: voriconazole 0,25ug/mL). CONCLUSION: Because of the main side effect of alemtuzumab is immunosuppression, we have to research fungal infections such as Aspergillosis, particularly in patients with fever resistant to common antibiotherapy.
OBJECTIVE: Treatment of chronic lymphocytic leukaemia (CLL) is rapidly evolving, with emerging new drugs. Alemtuzumab is a monoclonal antibody recognizing CD52 antigen approved in the treatment of relapsing-refractory CLL. A frequent side effect is the immunosuppression and patients treated with alemtuzumab risk to develop fungal infections such as aspergillosis. PATIENT AND METHODS: This case report is about a patient who developed an uncommon localization of aspergillosis: prostatic and renal, after a treatment by alemtuzumab monotherapy. During the week 8 of alemtuzumab, the patient presented fever, urinary frequency and urologic symptoms. Persistance of fever with common antibiotherapy led to realize a tomography that showed prostatic and renal abscess (70mm and 29mm). It was decided to realize a prostatic biopsy. RESULTS: Histological findings showed suppurative abscess with ischemic necrosis and fungal proliferation, with branched fungal hyphae. Direct examination was negative. Culture on Sabouraud's agar revealed a mould identified as Aspergillus fumigatus. The organism was susceptible to voriconazole (MIC: voriconazole 0,25ug/mL). CONCLUSION: Because of the main side effect of alemtuzumab is immunosuppression, we have to research fungal infections such as Aspergillosis, particularly in patients with fever resistant to common antibiotherapy.
Authors: Jiaojiao Zhang; Jing Luo; Xiangqin Weng; Yongmei Zhu; Gaurav Goyal; Fabiana Perna; Manuel Espinoza-Gutarra; Lu Jiang; Li Chen; Jian-Qing Mi Journal: Ann Transl Med Date: 2022-06
Authors: Thomas J Matula; Yak-Nam Wang; Tatiana Khokhlova; Daniel F Leotta; John Kucewicz; Andrew A Brayman; Matthew Bruce; Adam D Maxwell; Brian E MacConaghy; Gilles Thomas; Valery P Chernikov; Sergey V Buravkov; Vera A Khokhlova; Keith Richmond; Keith Chan; Wayne Monsky Journal: Ultrasound Med Biol Date: 2020-11-26 Impact factor: 2.998
Authors: Maciej Borówka; Stanisław Łącki-Zynzeling; Michał Nicze; Sylwia Kozak; Jerzy Chudek Journal: Cancers (Basel) Date: 2022-08-23 Impact factor: 6.575